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CORRECTIONS
Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB, for the Intermountain Heart
Collaborative (IHC) Study Group. Which White Blood Cell Subtypes Predict Increased Cardiovascular Risk? J Am Coll Cardiol
2005;45:1638–43.
On page A30 of the Condensed Abstracts Table of Contents, the second sentence should have read:
Among 3,227 patients, WBC count was confirmed to independently predict death/MI in patients with or at high risk for coronary artery
disease, but a greater predictive ability was provided by high neutrophil (fourth quartile6.6103 l) or low lymphocyte counts (2.2-fold
increase for fourth quartile compared with first quartile of neutrophil/lymphocyte ratio).
In the Abbreviations and Acronyms box, L should have been identified as lymphocyte.
In the legend to Figure 1, N/L should have been defined as neutrophil/lymphocyte.
doi:10.1016/j.jacc.2005.06.013
Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleinman N, Feit F, Wolski K, Bittl JA, Wilcox R, Topol EJ,
Lincoff AM, for the REPLACE-2 Investigators. Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With
Diabetes Mellitus: An Analysis From the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to
Reduced Clinical Events (REPLACE)-2 Trial. J Am Coll Cardiol 2005;45:1932–8.
In the Results section of the Abstract, the last sentence should read: “There was less minor bleeding in the bivalirudin arm in diabetic
patients (12.6%) vs. 24.4%, p  0.001), whereas no difference was seen in the incidence of major bleeding (3.0% vs. 3.3%, p  0.69).”
In the Results section of the text, the third sentence of the Bleeding Outcomes section should read: “Among the diabetic patients, major
bleeding was seen in 25 (3.0%) of patients randomized to the bivalirudin arm and 26 (3.3%) of those randomized to the GP IIb/IIIa
inhibitor arm (p  0.69), whereas among the non-diabetic patients, this occurred in 2.14% in the bivalirudin arm versus 4.42% in the GP
IIb/IIIa inhibitor arm (p  0.001).”
doi:10.1016/j.jacc.2005.06.018
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